A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive ...
Dec 10, 2014
0
0
A drug which targets a key gene fault could halt an aggressive womb cancer and shrink tumours, according to research published in the British Journal of Cancer.
Sep 30, 2014
0
0
Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with ...
Sep 29, 2014
0
0
The breast cancer drug trastuzumab emtansine (also known as Kadcyla) will not be made routinely available on the NHS following a failure to reach an agreement on price between the National Institute for Health and Care Excellence ...
Aug 11, 2014
0
0
(Medical Xpress)—For the first time, researchers from Queen Mary University of London (QMUL) have revealed the molecule αvβ6 (alpha v beta 6) plays a fundamental role in helping breast cancer cells to grow and spread. ...
Jul 4, 2014
0
0
For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells—specifically those testing positive for human epidermal growth factor receptor 2 (HER2). A recent ...
Jun 9, 2014
0
0
In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers ...
Jun 1, 2014
0
0
(Medical Xpress)—A common compound known to fight lymphoma and skin conditions actually has a second method of action that makes it particularly deadly against certain aggressive breast tumors, researchers at Duke Medicine ...
Feb 18, 2014
0
0
Research led by the Translational Genomics Group at Vall d'Hebron Institute of Oncology (VHIO) in Barcelona has not only shown that HER2+ breast cancer can be classified into four different subtypes, but also unmasked a subtype ...
Jan 17, 2014
0
0
(Medical Xpress)—Recently some intriguing data has suggested that breast cancer patients whose tumors appear insensitive to a class of drugs known as anti-HER2 medications (the drug trastuzumab, marketed as Herceptin, is ...
Nov 18, 2013
0
0
